These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 697920)

  • 21. Platelet monoamine oxidase and plasma amine oxidase in psychiatric patients.
    Meltzer HY; Arora RC; Jackman H; Pscheidt G; Smith MD
    Schizophr Bull; 1980; 6(2):213-9. PubMed ID: 7375852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Platelet monoamine oxidase activity in schizophrenic patients.
    Becker RE; Shaskan EG
    Am J Psychiatry; 1977 May; 134(5):512-7. PubMed ID: 848577
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular background and physiological consequences of altered peripheral serotonin homeostasis in adult rats perinatally treated with tranylcypromine.
    Blazevic S; Erjavec I; Brizic M; Vukicevic S; Hranilovic D
    J Physiol Pharmacol; 2015 Aug; 66(4):529-37. PubMed ID: 26348077
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of tranylcypromine stereoisomers on monamine oxidation in man.
    Reynolds GP; Rausch WD; Riederer P
    Br J Clin Pharmacol; 1980 May; 9(5):521-3. PubMed ID: 7397067
    [No Abstract]   [Full Text] [Related]  

  • 25. Platelet monoaminooxidase activity and behavioural characteristics in humans.
    Castrogiovanni P; Maremmani I; Bongioanni P; Marazziti D
    Neuropsychobiology; 1990-1991; 23(4):173-6. PubMed ID: 2130285
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Platelet monoamine oxidase activity in neuroleptic-naive schizophrenic patients: lack of influence of chronic perphenazine treatment.
    Spivak B; Kosower N; Zipser Y; Shreiber-Schul N; Apter A; Tyano S; Weizman A
    Clin Neuropharmacol; 1994 Feb; 17(1):83-8. PubMed ID: 8149362
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors affecting determination of platelet monoamine oxidase activity.
    Jackman HL; Meltzer HY
    Schizophr Bull; 1980; 6(2):259-66. PubMed ID: 6103575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Platelet monoamine oxidase activity in epilepsy.
    Kruk ZL; Moffett A; Scott DF
    J Neurol Neurosurg Psychiatry; 1980 Jan; 43(1):68-70. PubMed ID: 7354360
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Platelet monoamine oxidase in chronic schizophrenic patients.
    Berger PA; Ginsburg RA; Barchas JD; Murphy DL; Wyatt RJ
    Am J Psychiatry; 1978 Jan; 135(1):95-9. PubMed ID: 618534
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of tricyclic antidepressants upon human platelet monoamine oxidase.
    Edwards DJ; Burns MO
    Life Sci; 1974 Dec; 15(12):2045-58. PubMed ID: 4621003
    [No Abstract]   [Full Text] [Related]  

  • 31. The use of monoamine oxidase inhibition to estimate megakaryocyte-platelet regeneration time (MPRT).
    Chamberlain KG; Tong M; Chiu E; Penington DG
    Thromb Res; 1988 Feb; 49(4):425-35. PubMed ID: 3381201
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kinetic aspects of human platelet monoamine oxidase thermolability.
    Wahlund LO; Sääf J; Ross SB; Wetterberg L; Smedby Y
    Acta Physiol Scand; 1984 Oct; 122(2):97-102. PubMed ID: 6516876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rate of metabolism of adrenaline and 5-hydroxytryptamine by blood platelets.
    Lahovaara S; Paasonen MK; Airaksinen MM
    Ann Med Exp Biol Fenn; 1968; 46(3):453-6. PubMed ID: 5734249
    [No Abstract]   [Full Text] [Related]  

  • 34. Platelet MAO activity in alcoholic patients and their first-degree relatives.
    Alexopoulos GS; Lieberman KW; Frances RJ
    Am J Psychiatry; 1983 Nov; 140(11):1501-4. PubMed ID: 6625002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of temperature on human platelet monoamine oxidase.
    Kobayashi K; Kohsaka M; Eiduson S
    Biochem Med; 1979 Aug; 22(1):59-63. PubMed ID: 496931
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect of neuroleptic drugs on platelet monoamine oxidase in psychiatric patients.
    Meltzer HY; Duncavage MB; Jackman H; Arora RC; Tricou BJ; Young M
    Am J Psychiatry; 1982 Oct; 139(10):1242-8. PubMed ID: 6127035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Substrate- and inhibitor-related characteristics of human platelet monoamine oxidase.
    Donnelly CH; Murphy DL
    Biochem Pharmacol; 1977 May; 26(9):853-8. PubMed ID: 861051
    [No Abstract]   [Full Text] [Related]  

  • 38. A method for the determination of platelet and plasma monoamine oxidase in whole blood.
    Marshall EF; Campbell IC
    Biochem Pharmacol; 1977 Feb; 26(4):353-4. PubMed ID: 849328
    [No Abstract]   [Full Text] [Related]  

  • 39. Human platelet MAO in drug-free and medicated schizophrenic patients.
    Friedhoff AJ; Miller JC; Weisenfreund J
    Am J Psychiatry; 1978 Aug; 135(8):952-5. PubMed ID: 27104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tranylcypromine isomers in the treatment of Parkinson's disease. Biochemical effects.
    Reynolds GP; Riederer P
    Int Pharmacopsychiatry; 1981; 16(1):30-3. PubMed ID: 7298269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.